In this study, we provide new evidence that the FAM167A/DSG1 axis regulates the noncanonical NF-κB pathway and governs BCR-ABL-independent TKI resistance in CML. Here, NFKB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.